Ocugen Investor Relations Material
Latest events
Q2 2025
Ocugen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ocugen Inc
Access all reports
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure blindness diseases. The company's lead product candidate is OCUL-001, an adeno-associated virus vector-based gene therapy for the treatment of wet age-related macular degeneration. The company is also engaged in the discovery, design, development and clinical trial advancement of additional AAV and complementary non-AAV gene therapies for retinal diseases, including EIPAO-203 and EPAC1. The company is headquartered in Malvern, Pennsylvania.
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
OCGN
Country
🇺🇸 United States